CD274 and cancer: These are indications that currently fare poorly with PD-1/PD-L1 immunotherapy (Jiang et al., 2018), and thus NC410 could benefit an entirely new class of cancer patients when used as either a monotherapy or in combination with checkpoint inhibitors.